InterMune (Nasdaq: ITMN) reported upbeat results for a late stage clinical trial of its lung disease treatment pirfenidone sending shares of the biotechnology company soaring $4.30 to close at $16.17.
Upbeat Trial Results For InterMune
February 03, 2009 at 17:21 PM EST
